Abstract
Objective To evaluate the improvement of health status in patients with rheumatoid arthritis (RA) treated with tocilizumab.Methods Thirty-nine patients were treated with 8 mg/kg tocilizumab every 4 weeks for 24 weeks. Disease activity was assessed by Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI). Improvement of health status was assessed by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36).Results Tocilizumab improved CDAI and SDAI significantly at week 4 compared with at baseline. In the components of AIMS-2, “physical score”, “symptom” and “affect” improved significantly at week 4 compared with at baseline, while “social interaction” did not improve significantly during 24 weeks of tocilizumab therapy. Similarly in SF-36, “bodily pain”, “general health”, “vitality” and “mental health” improved significantly at week 4. The most correlative component of AIMS-2 with CDAI was “symptom”, while “social interaction” did not correlate with CDAI during tocilizumab treatment.Conclusion The time-course diversity in improvement of health status should be considered to provide proper healthcare when treated with tocilizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
